Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ABIO · Entity 3781 | VP, Finance | December 21, 2020 | December 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date December 21, 2020 · Filed December 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2030-12-21 | Direct | 55,000 |
Reported balance
After 2020-12-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-21 · Grant · Acquired 55,000 · Balance 55,000 F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 48 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 48 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2020 Filed Dec 23, 2020 21:15 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001209191-20-065001 · doc4.xml · derivative · entry 1 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-12-21 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 48 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 21:00 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 1,114 | $0.50 | $556.33 |
DisclosureSEC source: 0001209191-18-023118 · doc4.xml · nonDerivative · entry 1 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:00 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 161 | $0.53 | $85.33 |
DisclosureSEC source: 0001209191-18-015074 · doc4.xml · nonDerivative · entry 1 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") F2 · balance_after: Includes remaining 1,114 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:15 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 1,114 | $2.46 | $2,740.44 |
DisclosureSEC source: 0001209191-17-025624 · doc4.xml · nonDerivative · entry 1 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) remaining 161 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) remaining 1,114 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:12 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 24,100 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015990 · doc4.xml · derivative · entry 2 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock · 24,100 shares Expires 2027-02-26 F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan, 50% vesting upon achievement of certain pre-specified corporate milestone related to the outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, and if the milestone is achieved, the remainder of the grant will vest on March 31, 2018, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. If the corporate milestone is not achieved, the Option will be cancelled. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:12 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 161 | $2.56 | $412.16 |
DisclosureSEC source: 0001209191-17-015990 · doc4.xml · nonDerivative · entry 1 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,389 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) remaining 161 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) 2,228 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:52 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-17-012760 · doc4.xml · derivative · entry 2 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2027-02-15 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:06 UTC | Oruka Therapeutics, Inc. ABIO · Entity 3781 | SaleCommon Stock | 476 | $2.91 | $1,385.16 |
DisclosureSEC source: 0001209191-16-142255 · doc4.xml · nonDerivative · entry 1 Selby Brian L. · CIK 0001628992 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,550 F1 · shares: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan") F2 · balance_after: Includes (i) remaining 322 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (ii) 2,228 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.